FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953669190> ?p ?o ?g. }

• W2953669190 endingPage "89" @default.
• W2953669190 startingPage "84" @default.
• W2953669190 abstract "Background and purpose Standard treatment of epidermoid anal cancer is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT). This phase I study aims to evaluate the addition of panitumumab (Pmab) to CRT and to determine the maximum tolerated dose (MTD) of Pmab and 5-FU in combination with CRT. Materials and methods Immunocompetent patients with locally advanced tumour without metastases (Stage T2, T3 or T4, whatever N stage; Stage N1–N3 whatever T stage) followed two RT periods (45 Gy in 5 weeks and 20 Gy in 2 weeks, separated by a 2-week break) with concomitant CT sessions of 5FU/MMC at RT weeks 1, 5 and 8. Pmab was administered on RT weeks 1, 3, 5, 8 and 10 according to a predefined dose escalation schedule. Results Ten patients were enroled. One was excluded due to unmet dose constraints respect. Three patients received dose level (DL) 0 (Pmab 3 mg/kg + 5FU 600 mg/m2/day) and six received DL-1 (Pmab 3 mg/kg + 5FU 400 mg/m2/day). Dose-limiting toxicities occurred in all patients at DL 0 and 2 at DL-1. Most common grade 3–4 toxicities observed at DL 0 were haematologic (100%), dermatitis (67%), and anaemia (67%). No death occurred. Four months after ending CRT, five and two patients had a local complete response and a partial response, respectively. One patient had a colostomy with abdomino-perineal amputation due to a tumour recurrence. Conclusions The MTD is 5FU at 400 mg/m2/day, MMC at 10 mg/m2 and Pmab at 3 mg/kg. The effect of the MTD on tumour response is evaluated in the phase 2 study." @default.
• W2953669190 created "2019-07-12" @default.
• W2953669190 creator A5001356881 @default.
• W2953669190 creator A5005521442 @default.
• W2953669190 creator A5008863246 @default.
• W2953669190 creator A5009433246 @default.
• W2953669190 creator A5015076102 @default.
• W2953669190 creator A5021364113 @default.
• W2953669190 creator A5031132493 @default.
• W2953669190 creator A5032193447 @default.
• W2953669190 creator A5034184218 @default.
• W2953669190 creator A5038199519 @default.
• W2953669190 creator A5040985815 @default.
• W2953669190 creator A5063565613 @default.
• W2953669190 creator A5076309223 @default.
• W2953669190 creator A5076574340 @default.
• W2953669190 creator A5082556359 @default.
• W2953669190 date "2019-11-01" @default.
• W2953669190 modified "2023-10-17" @default.
• W2953669190 title "Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904)" @default.
• W2953669190 cites W1804130247 @default.
• W2953669190 cites W1947979503 @default.
• W2953669190 cites W1977066759 @default.
• W2953669190 cites W2029919879 @default.
• W2953669190 cites W2045804591 @default.
• W2953669190 cites W2050000965 @default.
• W2953669190 cites W2055442814 @default.
• W2953669190 cites W2065481133 @default.
• W2953669190 cites W2067126590 @default.
• W2953669190 cites W2076341925 @default.
• W2953669190 cites W2078636594 @default.
• W2953669190 cites W2119237890 @default.
• W2953669190 cites W2124675713 @default.
• W2953669190 cites W2126992087 @default.
• W2953669190 cites W2154131697 @default.
• W2953669190 cites W2158244375 @default.
• W2953669190 cites W2164644812 @default.
• W2953669190 cites W2204346774 @default.
• W2953669190 cites W2509389325 @default.
• W2953669190 cites W2565526207 @default.
• W2953669190 cites W2579647781 @default.
• W2953669190 cites W2727638442 @default.
• W2953669190 cites W2734526782 @default.
• W2953669190 cites W2789358024 @default.
• W2953669190 cites W2794104347 @default.
• W2953669190 cites W2795734554 @default.
• W2953669190 cites W2796394679 @default.
• W2953669190 cites W776995397 @default.
• W2953669190 doi "https://doi.org/10.1016/j.radonc.2019.05.018" @default.
• W2953669190 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31185328" @default.
• W2953669190 hasPublicationYear "2019" @default.
• W2953669190 type Work @default.
• W2953669190 sameAs 2953669190 @default.
• W2953669190 citedByCount "11" @default.
• W2953669190 countsByYear W29536691902019 @default.
• W2953669190 countsByYear W29536691902020 @default.
• W2953669190 countsByYear W29536691902021 @default.
• W2953669190 countsByYear W29536691902022 @default.
• W2953669190 countsByYear W29536691902023 @default.
• W2953669190 crossrefType "journal-article" @default.
• W2953669190 hasAuthorship W2953669190A5001356881 @default.
• W2953669190 hasAuthorship W2953669190A5005521442 @default.
• W2953669190 hasAuthorship W2953669190A5008863246 @default.
• W2953669190 hasAuthorship W2953669190A5009433246 @default.
• W2953669190 hasAuthorship W2953669190A5015076102 @default.
• W2953669190 hasAuthorship W2953669190A5021364113 @default.
• W2953669190 hasAuthorship W2953669190A5031132493 @default.
• W2953669190 hasAuthorship W2953669190A5032193447 @default.
• W2953669190 hasAuthorship W2953669190A5034184218 @default.
• W2953669190 hasAuthorship W2953669190A5038199519 @default.
• W2953669190 hasAuthorship W2953669190A5040985815 @default.
• W2953669190 hasAuthorship W2953669190A5063565613 @default.
• W2953669190 hasAuthorship W2953669190A5076309223 @default.
• W2953669190 hasAuthorship W2953669190A5076574340 @default.
• W2953669190 hasAuthorship W2953669190A5082556359 @default.
• W2953669190 hasBestOaLocation W29536691901 @default.
• W2953669190 hasConcept C121608353 @default.
• W2953669190 hasConcept C126322002 @default.
• W2953669190 hasConcept C126894567 @default.
• W2953669190 hasConcept C141071460 @default.
• W2953669190 hasConcept C146357865 @default.
• W2953669190 hasConcept C151730666 @default.
• W2953669190 hasConcept C2776694085 @default.
• W2953669190 hasConcept C2778332735 @default.
• W2953669190 hasConcept C2778424827 @default.
• W2953669190 hasConcept C2779338040 @default.
• W2953669190 hasConcept C2779384505 @default.
• W2953669190 hasConcept C2779840525 @default.
• W2953669190 hasConcept C2779998722 @default.
• W2953669190 hasConcept C2780035688 @default.
• W2953669190 hasConcept C2780456651 @default.
• W2953669190 hasConcept C2781074409 @default.
• W2953669190 hasConcept C31760486 @default.
• W2953669190 hasConcept C509974204 @default.
• W2953669190 hasConcept C526805850 @default.
• W2953669190 hasConcept C71924100 @default.
• W2953669190 hasConcept C86803240 @default.
• W2953669190 hasConcept C90924648 @default.

• next